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Erythrina mulungu Benth. (Fabaceae), Cordia verbenacea A. DC. (Boraginaceae),
Solanum paniculatum L. (Solanaceae) and Lippia sidoides Cham. (Verbenaceae) are
medicinal plant species native to Brazil shortlisted by the Brazilian National Health
System for future clinical use. However, nothing is known about their effects in metabolic
and transporter proteins, which could potentially lead to herb-drug interactions (HDI).
In this work, we assess non-toxic concentrations (100 µg/mL) of the plant infusions
for their in vitro ability to modulate CYP3A4 mRNA gene expression and intracellular
glutathione levels in HepG2 cells, as well as P-glycoprotein (P-gp) activity in vincristine-
resistant Caco-2 cells (Caco-2 VCR). Their mechanisms of action were further studied
by measuring the activation of human pregnane X receptor (hPXR) in transiently co-
transfected HeLa cells and the inhibition of γ-glutamyl transferase (GGT) in HepG2
cells. Our results show that P-gp activity was not affected in any case and that only
Solanum paniculatum was able to significantly change CYP3A4 mRNA gene expression
(twofold decrease, p < 0.05), this being correlated with an antagonist effect upon hPXR
(EC50 = 0.38 mg/mL). Total intracellular glutathione levels were significantly depleted by
exposure to Solanum paniculatum (−44%, p< 0.001), Lippia sidoides (−12%, p< 0.05)
and Cordia verbenacea (−47%, p< 0.001). The latter plant extract was able to decrease
GGT activity (−48%, p < 0.01). In conclusion, this preclinical study shows that the
administration of some of these herbal medicines may be able to cause disturbances to
metabolic mechanisms in vitro. Although Erythrina mulungu appears safe in our tests,
active pharmacovigilance is recommended for the other three species, especially in the
case of Solanum paniculatum.
Keywords: herbal medicines, Brazil, glutathione, CYP3A4, P-Glycoprotein, drug metabolism
INTRODUCTION
According to the World Health Organization (WHO), 65–80% of the world’s population in
developing countries depends on medicinal plants for their primary health care due to poverty
or lack of access to modern medicine (Silveira et al., 2008). Latin American countries possess an
enormous part of the world’s biodiversity, with Brazil alone containing approximately 22% of all
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existing plants and microorganisms on earth (Calixto, 2005). For
the past 10 years, Brazilian health care authorities have directed
their attention to the considerable use of medicinal plants in hope
to integrate traditional Brazilian medicine into the public health
care system (SUS). Indeed, there is a growing demand for the use
of medicinal plants by the citizens of Brazil as well as an interest
in natural products to support healthier lifestyles (Silveira et al.,
2008).
Since 2004, the SUS, along with the Ministry of Health
(MoH), have created a National Policy on Integrative and
Complementary Practices (PNPIC), which is aimed at offering
traditional medicinal plants as a treatment option through the
SUS with guaranteed safety and quality (Balbino and Dias, 2010).
The MoH and the SUS surveyed municipalities nationwide and,
using indications according to categories of the International
Classification of Diseases, created the National List of Medicinal
Plants of Interest to SUS (RENISUS)1. This list is composed
of 71 plants, which have the potential to generate products of
interest for the SUS, as well as promote the traditional practice
of herbal remedies. In the same year, the Brazilian Health
Surveillance Agency (ANVISA) began to regulate the registration
of herbal medicines, requiring quality control and safety reports
confirming good manufacturing practice for all herbal medicines
(Oliveira et al., 2006). As a result of this advancement, the first
phytomedicine to be fully developed in Brazil was approved by
ANVISA. It is an anti-inflammatory topical ointment marketed
as Acheflan R©, in which the active ingredient is the Brazilian
medicinal plant Cordia verbenacea DC (Boraginaceae), a plant
analyzed in this study (Calixto, 2005).
Plant species included in the RENISUS list are prioritized
to undergo safety and efficacy studies. To date, very little is
known about the effects they may cause on phase 1 and phase 2
metabolism and transporter proteins. Also, the pharmacokinetic
(PK) profile of herbal medicines is virtually impossible to study as
they are Complex Chemical Entities, i.e., consisting of numerous
chemicals with disparate absorption rates, pharmacodynamic
(PD) and PK properties (He et al., 2011). Therefore, the
preclinical approach should clarify whether herbal medicines can
alter the activity and expression of discrete metabolic and/or
transporter proteins in order to theorize which prescription drugs
(single chemical entities) would be affected by their concomitant
use.
Since CYP3A4 metabolizes most of the currently marketed
drugs, glutathione is a central player in drug conjugation and
P-glycoprotein (P-gp) activity determines drug absorption, most
of the preclinical safety studies of natural and synthetic drugs
focus on these targets (Zhou, 2008; Glaeser, 2011; Lu, 2013).
Such data is necessary in order to predict and avoid
interactions that may occur between the extracts and
conventional drugs. These types of interactions are called
herb-drug interactions (HDI) (Mazzari and Prieto, 2014b). In a
previous literature review, we revealed that such data are known
for only half of the medicinal plants traditionally used in Brazil
1SUS (2009). Relação Nacional de Plantas Medicinais de Interesse ao SUS
(RENISUS), Brasilia. Available at: http://bvsms.saude.gov.br/bvs/sus/pdf/marco/
ms_relacao_plantas_medicinais_sus_0603.pdf [accessed February 22, 2016].
(Mazzari and Prieto, 2014a). In order to fill this information gap,
we embarked on a study of 24 medicinal plants for which no
information of this sort was found. Here we report on our results
for four native plants on RENISUS, namely Erythrina mulungu
Benth. (Fabaceae), Cordia verbenacea A. DC. (Boraginaceae),
Solanum paniculatum L. (Solanaceae) and Lippia sidoides Cham.
(Verbenaceae), which are used in the treatment of symptoms
ranging from anxiety to gastric dysfunctions (Table 1).
MATERIALS AND METHODS
Chemicals and Reagents
Cell Culture
HepG2 and Caco-2 cell lines were from Sigma Aldrich at passages
100 and 43 respectively. HeLa cells were donated by Dr. Paul
Webb from the Houston Methodist Institute for Technology at
passage 20. All cell culture reagents were from Gibco R© Invitrogen
unless otherwise stated. Vincristine 2 mg/mL was purchased from
Hospira Ltd.
HPTLC Analysis
Water, Dichloromethane (>99.8%, contains amylene as a
stabilizer), ethyl acetate (>99.7%) and methanol (>99.9%)
all ChromasolvPlus for HPLC provided by Sigma Aldrich.
Acetic acid (glacial) analytical reagent grade provided by Fisher
Scientific. Formic Acid 98% provided by Rectapur R© VWR.
Caffeic acid was from Kotch-light Laboratories LTD. Rutin
hydrate, quercetin dehydrate and gallic acid all from Sigma
Aldrich. Diphenylborinic acid 2-aminoethyl ester (98%) and
coumarin laser grade (99% UV-Vis) were provided by ACROS
organics. Luteolin (HPLC grade) was from Extrasynthése.
Chlorogenic acid provided by Cayman Chemical Co. Poly-
ethylene glycol 4000 grade was from Fisher Scientific.
Cell Viability Assays
Sulphorhodamine B (SRB), Neutral Red (NR), (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide)
(MTT), trichloroacetic acid (TCA), glacial acetic acid, 96%
ethanol, hydrochloric acid (HCl), Isopropanol and Tris base were
from Sigma Aldrich.
CYP3A4 mRNA Gene Expression Assay
Oligonucleotide primers were custom-synthesized by Invitrogen
Life Technologies and Sigma Aldrich. TRIzol R© (Total RNA
Isolation Reagent), Oligo (dT) 12-18 primers, M-MLV Reverse
Transcriptase, RNAseOUT, DNAse I Amplification Grade and
100 mM dNTP Set were purchased from Invitrogen Life
Technologies. SYBR Green (2xqPCR Master Mix premixed with
SYBRgreen) was obtained from Amethyst reagents (Cambridge
Bioscience). Rifampicin and DMSO were purchased from Sigma
Aldrich.
hPXR Assay
Lipofectamine R© 2000 was purchased from Invitrogen. Rifampicin
and Luciferase assay system were obtained from Sigma Aldrich
and Promega, respectively.
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Intracellular Glutathione Assay
Buthionine sulfoximine (BSO), L-glutathione reduced,
glutathione reductase, 5-5′-dithiobis(2-nitrobenzoic acid)
(DTNB), β-Nicotinamide adenine dinucleotide 2′-phosphate
reduced tetrasodium salt hydrate (NADPH), Triton-X and
sulfosalicylic acid were from Sigma Aldrich.
GGT Activity Assay
L-Glutamic acid γ-(p-nitroanilide) hydrochloride, 4-nitroaniline,
glycyl-glycine (Gly-Gly), Tris base and acivicin were from Sigma
Aldrich.
Rhodamine 123 Uptake Assay
Rhodamine 123 was from Sigma Aldrich. Verapamil (Securon IV
2.5 mg/mL) was from Abbott Laboratories Ltd.
Plant Materials and Extraction
Plant materials were collected from “Farmácia Viva Brasília”
(Brasília, DF – Brazil); via the University of Brasília – UnB. The
plants were grown and processed according to good practices,
ensuring validity and quality2.
All whole plant handling and extraction were performed at
UnB. Aerial parts of the plants (100 g) were subjected to a 20 min
infusion, to mimic traditional use. The infusions were filtered,
lyophilized, and immediately sent to UCL School of Pharmacy.
The extracts were stored at−18◦C throughout the studies.
Special permission must be granted from the Brazilian Council
for Management of Genetic Heritage (CGEN) in order to have
access to genetic material, respecting international intellectual
and genetic property rights laws. Access was authorized
(license n. 010295/2014-3) resulting from collaboration between
University College London (UCL) and UnB. Access was granted
on May 2014, and the plant extracts were received on June 2014.
HPTLC Analysis
Extracts were diluted to a concentration of 50 mg/mL in
methanol. Control compounds were made at a concentration
of 1mg/mL, also diluted in methanol. A CAMAG Linomat
5 was used to apply 5 µL of the samples to TLC silica
gel 60 F254 aluminum sheets. The plates were developed
using a CAMAG ADC2 automatic developing chamber. The
method included 30-s pre-drying, 10min humidity control using
magnesium chloride to 48.3% relative humidity and 20 min
saturation time, using saturation pads all done at 25.2◦C. The
mobile phase used was ethyl acetate: formic acid: water (82:9:9).
During development, the solvent front was allowed to migrate
80 mm before a drying time of 5 min. For derivatization, we
used Natural products reagent (NPR) followed by PEG 4000
(Reich and Schibli, 2007). All visualization and analysis were
done using CAMAG TLC visualizer both before and after
derivatization.
2SUS (2010). Ministério da Saúde. Portaria 886, de 20 de abril de 2010.
Institui a Farmácia Viva no âmbito do Sistema Único de Saúde. Available
at: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2010/prt0886_20_04_2010.html
[accessed February 22, 2016].
Cells Culture
HepG2 cells were cultured in Minimal Essential Medium
(MEM) Alpha supplemented with 10% fetal bovine serum (FBS),
100 U/mL penicillin, 100 µg/mL streptomycin. Caco-2 cells were
cultured in Dulbecco’s Minimum Essential Medium (DMEM)
with high glucose (4.5g/L) and L-glutamine supplemented with
10%FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, 1% non-
essential amino acids (NEEA) and Vincristine (50 µM). HeLa
cells were cultured in DMEM media supplemented with 10% FBS,
100 U/mL penicillin, 100 µg/mL streptomycin. All cell lines were
kept in the NuAire DH Autoflow CO2 Air-Jacketed incubator at
37◦C/5%CO2.
Cell Viability Assays
The SRB, NR and MTT assays were performed as previously
described (José Ruiz et al., 2006; Houghton et al., 2007; Repetto
et al., 2008).
Real-Time RT-qPCR Analysis
mRNA Extraction and cDNA Synthesis
After exposing HepG2 cells (5 × 105 cells/well) to plant extracts
or the CYP3A4 inducer Rifampicin (50 µM) or the CYP 3A4
inhibitor DMSO 1% for 96 h, total RNA was extracted from
using TRIzol R© Reagent according to the manufacturer’s protocol.
Samples were treated with DNase I (1 U/µL) to avoid genomic
contamination. The quantity and quality of RNA was determined
by differential readings at 260 and 280 nm in a Nanodrop 2000
(Thermo Scientific). The integrity of total RNA from HepG2 cells
was assessed by visual inspection of the two rRNAs 28 and 18 s
on agarose gels. cDNA was synthesized from 1 µg of total RNA
with the Moloney rine Leukemia Virus Reverse Transcriptase (M-
MLV RT) (200 U/µL) and oligo(dT) 12-18 primer (0.5 µg/µL),
according to the manufacturer’s instruction in a final volume of
21 µL.
RT-qPCR Conditions and Analysis
CYP3A4 sense strand primer sequence was 5′-CAAGGACAA
CATAGATCGTTACATATACACACCCTTTGGAAG-3′ and the
antisense strand primer was 5′-AGCTCAATGCATGTACA
GAATCCCCGGTTA-3′ (Usui et al., 2003). The β-actin gene
was used to control for variations in RNA loading within the
experimental conditions. The sense strand primer sequence was
5′-CGTACCACTGGCATCGTGAT-3′ and the antisense strand
primer was 5′-GTGTTGGCGTACAGGTCTTTG-3′. The RT-
qPCR was carried out in 96-well plates using a PikorealTM
Real-Time PCR detection system (Thermo Scientific). Each well
contained a final reaction volume of 10 µL (5.0 µL MasterMix
with SYBR Green, 2.0 µL cDNA template diluted appropriately,
0.5 µL of each primer at a final concentration 0.3 mM and
2.0 µL of RNAse/DNAse free distilled water). PCR reaction was
performed under the following schema: initial denaturation at
95◦C for 2 min, then 40 cycles of denaturation at 95◦C for 15 s,
annealing at 55◦C (β-actin) or 60◦C (CYP3A4) for 30 s, and
extension at 72◦C for 30 s.
At the end of the run, a melting curve was generated by heating
the amplicon from 60 to 95◦C in order to confirm the specificity
of the amplification for each primer pair. All RT-qPCR were run
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in quadruplicates. Standard curves were produced to check the
PCR efficiency using a fivefold dilution series of cDNA. Efficiency
(E) of primer pairs was obtained from the slope of the calibration
curve generated. The relative expression was calculated on the
basis of ‘delta delta Ct’ (11Ct) values. Normalization of the
target gene was achieved by using β-actin as a reference gene.
hPXR Activation Assay
After 24 h seeding, HeLa cells (4× 104 cells/well) were transiently
co-transfected with 60 ng of pM-Gal4-PXR-LBD and 240 ng
of Gal4 luciferase reporter using lipofectamine 2000 reagent
according to the manufacturer’s protocol. Transfected cells were
treated with increasing concentrations of plant extract and/or
rifampicin 1 µM (EC50). Luciferase activity was measured after
24 h, according to manufacturer’s protocol in a 20/20 n Glomax
luminometer and reported as a response (%) compared to cells
treated only with rifampicin.
Intracellular Glutathione Levels
The method used in the intracellular determination of
glutathione levels was adapted from those described by Allen
et al. (2000) and Rahman et al. (2006) with slight modifications.
After 24 h incubation with BSO (10 µM) or plant extracts
(100 µg/mL), HepG2 cells (4 × 104 cells/well) were washed
with PBS and 60 µL of 0.1% Triton-X was added to each well
of the plates to lyse the cells. Twenty five micro liter of 5%
sulfosalicylic acid was added to the cell lysates and plates were
shaken for 2 min. Twenty five micro liter of glutathione reaction
buffer containing NADPH (2.39 mM), DTNB (0.01 M) and
glutathione reductase (500UI) in sodium phosphate buffer
(143 mM) containing EDTA (6.3 mM) was added to the cell
lysates. Absorbance was read in a kinetic cycle in the plate reader
every 30 s for 5 min at 405 nm (11 readings). Absorbances
were converted into absolute amounts by means of the i-slopes
method using known concentrations of L-glutathione reduced.
GGT Activity Assay
GGT activity assay was conducted according to Rebbeor et al.
(1998) with slight modifications. Briefly, after 24 h incubation of
HepG2 cells (1 × 106 cells/well) with the GGT inhibitor acivicin
(5 µM) or plant extracts (100 µg/mL), media was aspirated
and cells were washed with PBS. Four milliliter of pre-warmed
glycylglicine buffer (115 mM Tris, 138mM glycylglycine) and
400 µL of the substrate γ-glutamyl-p-nitroanilide (29.6 mg/mL
of HCl 0.5 mmol/L) were added to the wells and plates were
incubated for 10 min. Then, 500 µL of the content of each well
were transferred to 24-well plates and absorbance was measured
in the plate reader (405 nm). Absorbances were converted
into absolute amounts by means of a calibration line using
4-nitroaniline.
Rhodamine 123 Uptake Assay
Rhodamine uptake/eﬄux assays were conducted as described by
Chieli et al. (1993) with minor modifications. After five passages
in media containing vincristine (50 µM), Caco-2 VCR (Eneroth
et al., 2001) cells (1 × 104 cells/well) were incubated for 2 h
with the P-gp inhibitor verapamil (20 µM) or plant extracts
(100 µg/mL) in serum-free media containing rhodamine 123
(5 µg/mL). After incubation, cells were washed with verapamil
(20 µM) in PBS. Cells were lysed with 100 µL of 0.1% Triton
X-100 in PBS and the plates were placed in the incubator for
15 min. The fluorescence intensity of cell lysates was measured
in the plate reader (Exc-485 nm, Em-525 nm). The cellular
accumulation of rhodamine 123 for each of the extracts was
expressed as the percentage of the accumulation measured for
rhodamine 123 under control conditions.
Statistical Analysis
Collected data were analyzed as means ± SD of at least three
independent experiments. Statistical significance was measured
by student t-test and ANOVA followed by Bonferroni correction
using GraphPad InStat (GraphPad Software Inc., La Jolla, CA,
USA). Results with a value of p < 0.05 were considered
significant.
RESULTS
Yield of Plant Extracts
Yields of herbal extracts were as follows: E. mulungu (5.77%),
Solanum paniculatum (9.27%), Lippia sidoides (13.33%) and
Cordia verbenaceae (14.95%).
HPTLC Analysis
Cordia verbenaceae fingerprint contains caffeic acid at retention
factor (Rf) = 0.87 and chlorogenic acid at Rf = 0.38. Solanum
paniculatum contains gallic acid at Rf = 0.81, rutin at Rf = 0.20
and chlorogenic acid at Rf = 0.38. Lippia sidoides contains
luteolin at Rf= 0.86 and minor amounts of quercetin at Rf= 0.90.
E. mulungu did not contain any of these metabolites in significant
amounts (see Figure in Supplementary Material).
Cell Viability
HepG2, Caco-2VCR, and HeLa cells exhibited more than 80%
viability after 24 h incubation of 100 µg/mL of plant extracts.
This allowed us to work on all experiments at that non-toxic
concentration (Data presented as Supplementary Materials).
Real-Time qPCR Efficiency
Both CYP3A4 and β-actin primers sequences revealed the
specificity of target amplification. Baseline and threshold were
properly set. Standard curve demonstrated good regression
coefficient and efficiency (Data presented as Supplementary
Materials). Melting curve analysis revealed a single peak for each
pair of primers (Data presented as Supplementary Materials).
CYP3A4 mRNA Gene Expression
Rifampicin (50 µM), a known CYP3A4 inducer, was able
to significantly increase CYP3A4 expression in 4.95 folds
(p < 0.001). DMSO 1% inhibited CYP3A4 expression in 2.7
folds (p < 0.01). E. mulungu, Cordia verbenacea and Lippia
sidoides were not able to modulate CYP3A4 expression in a
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FIGURE 1 | CYP3A4 mRNA gene expression in HepG2 cells treated with rifampicin (50 µM), DMSO 1% and plant extracts (100 µg/mL). After 4 days
incubation with xenobiotics, CYP3A4 gene expression was determined as described in Section Real-Time RT-qPCR Analysis. Data are means ± SD; n = 4
experiments. ∗P < 0.05, ∗∗∗P < 0.001.
significant manner compared to non-treated cells. However,
Solanum paniculatum inhibited CYP3A4 mRNA gene expression
in 2.4 folds, showing a similar effect to DMSO 1% (p < 0.01)
(Figure 1).
hPXR Antagonistic Effect of Solanum
paniculatum
To further investigate whether the diminished expression of
CYP3A4 mRNA gene by Solanum paniculatum treatment was
mediated by an antagonist effect upon hPXR, we performed a
reporter gene assay. As we can observe, co-transfected HeLa cells
treated with rifampicin (1 µM) and serial dilutions of Solanum
paniculatum extract showed a dose-response inhibition upon
hPXR transcription activity. The maximal inhibition was close to
60% with a IC50 of 0.38 mg/mL (Figure 2).
Inhibition of hPXR reporter gene assay was not due to
interference of the extract with the luciferase activity, since it
did not show any effect on luciferase activity in HeLa cells
transfected with CMV-luciferase expression vector. Additionally,
this extract showed an agonist effect in HeLa cells co-transfected
with thyroid hormone receptor beta 1 ligand binding domain and
Gal4 luciferase reporter treated with triiodothyronine (T3). We
did not use Renilla luciferase assay as an internal control since
several authors have been describing the limitations of Renilla
luciferase as an internal control of transcription efficiency (Ho
and Strauss, 2004; Shifera and Hardin, 2010). This information is
presented as Supplementary Data.
We also evaluated the effect of the other extracts on
hPXR transcription activity. We observed that E. mulungu is
a hPXR partial agonist since it increased hPXR reporter gene
FIGURE 2 | Antagonistic effect of Solanum paniculatum extract on
rifampicin-induced hPXR activation. HeLa cells were co-transfected with
expression vector pM-Gal4-PXR-LBD and Gal4 luciferase reporter and treated
with increasing concentrations of Solanum paniculatum in the presence of
rifampicin 1 µM (EC50). Luciferase activity was measured after 24 h and
normalized as a percentage of rifampicin treated cells.
transcription activation in a dose dependent manner, but not as
strong as rifampicin; Lippia sidoides did not show any effect on
hPXR; Cordia verbenaceae failed to increase hPXR transcription
activity. When we treated the cells with Cordia verbenaceae
extract the transcription activity of rifampicin was impaired by
50% suggesting an antagonist effect. However, this is due to
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unspecific effects, since inhibition was also observed with a high
affinity thyroid hormone receptor (Supplementary Figure S16,
Supplementary Data).
Modulation of Intracellular Glutathione
Levels by Plant Extracts
As shown in Figure 3, Solanum paniculatum, Lippia sidoides and
Cordia verbenacea led to significant reduction of intracellular
glutathione levels. The declines seen in the cells treated with
Solanum paniculatum and Cordia verbenacea are statistically
comparable to BSO (10 µM) (p < 0.001). Lippia sidoides
also significantly inhibited the accumulation of glutathione
in cells (p < 0.05). E. mulungu, on the other hand, was
able to significantly increase the intracellular glutathione level
(p< 0.001).
GGT Activity Is Compromised by Cordia
verbenaceae
The GGT activity in HepG2 cells was significantly lowered by
Cordia verbenacea (p < 0.01). The GGT inhibitor acivicin was
able to reduce its activity in a concentration of 5 µM (p < 0.001)
(Figure 4).
P-gp Efflux Activity Is Not Affected by
the Plant Extracts
Overexpression of P-gp protein and the eﬄux activity in Caco-
2 VCR cells are confirmed by the results previously reported by
Eneroth et al. (2001) and by experiment conducted in our lab
(Data presented as Supplementary Materials). None of the plant
extracts could significantly modulate P-gp activity in Caco-2 VCR
cells at the tested concentration. The P-gp inhibitor verapamil
(20 µM) was able to significantly impair the eﬄux of rhodamine
123 (p< 0.001) (Figure 5).
DISCUSSION
In Brazil, information about potential interactions caused by
herbal medicines and conventional medicines alike, must be
clearly described in the patient information leaflet. Besides HDI,
other types of interactions should also be disclosed to the patient,
such as drug-food, drug-chemical substance, drug-laboratory and
non-laboratory test, and drug-disease interactions. Such data
is available for newly registered herbal medicines, which have
undergone preclinical and clinical tests. On the other hand,
similar studies are not yet available for herbal medicines that are
included in the ANVISA’s traditional herbal medicine list. In this
case, the regulatory approval from ANVISA is given without the
need of those studies.
To help in this endeavor, we investigate whether the four
selected Brazilian native medicinal plants can alter the activity
and/or expression of discrete metabolic and/or transporter
proteins in order to evaluate which prescription drugs (single
chemical entities) would be affected by their concomitant use.
Solanum paniculatum was the only medicinal herbal drug that
decreased CYP3A4 gene expression. We show that this down-
regulation is due –at least in part- to an antagonistic effect of
the plant extract on hPXR. CYP3A is the most relevant family of
phase 1 metabolism and CYP3A4 is responsible for metabolizing
more than 50% of marketed drugs (Wienkers and Heath, 2005).
hPXR is a nuclear receptor that plays a key role in the regulation
of xenobiotic-inducible CYP3A mRNA gene expression and most
FIGURE 3 | Intracellular glutathione levels after 24 h treatment with the plant extracts (100 µg/mL) and buthionine sulfoximine (10 µM) in HepG2 cells.
Data are means ± SD; n = 4 experiments. ∗P < 0.05, ∗∗∗P < 0.001.
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FIGURE 4 | γ-Glutamyl transferase (GGT) activity in HepG2 cells treated with acivicin (5 µM) or plant extracts (100 µg/mL). GGT activity was measured
on the surface of plated cells and the absorbances were converted into absolute amounts by means of a calibration line using 4-nitroaniline. Values are mean ± SD
(n = 4). ∗∗P < 0.01, ∗∗∗P < 0.001.
FIGURE 5 | Rhodamine 123 fluorescence in vincristine resistant Caco-2 cells (Caco-2 VCR). Caco-2 VCR cells were treated with the P-gp inhibitor
verapamil (20 µM) or plant extracts (100 µg/mL). Subsequently, cells were incubated with 5 µg/mL of rhodamine 123. Values are mean ± SD (n = 4).
cases of CYP3A4 gene regulation are related to the modulation of
hPXR (Dong et al., 2010).
Our results must be put into the context of the limitations
of HepG2 as a model for induction studies (Gerets et al., 2012).
Although less sensitive than human hepatocytes (HH), HepG2
line is able to express CYP3A4 mRNA under the conditions
established by Sumida et al. (2000). The poor response to
induction is overcome by the sensitivity of RT-PCR, and this
Frontiers in Pharmacology | www.frontiersin.org 8 August 2016 | Volume 7 | Article 265
fphar-07-00265 August 19, 2016 Time: 11:11 # 9
Mazzari et al. Pharmacokinetics of Brazilian Medicinal Plants
technique has been used for the study of natural products by
several authors such as Cui et al. (2014) and Kumagai et al.
(2016). Studies with HH should follow our screening to confirm
its potential clinical significance (Sumida et al., 2000; Gerets
et al., 2012; Cui et al., 2014; Kumagai et al., 2016). This could
be the reason that we can see some antagonistic effects for
E. mulungu in transfected HeLa cells but no modulation of
CYP3A4 gene expression in HepG2 cells (See Supplementary
Data).
Solanum paniculatum, together with Cordia verbenacea and
Lippia sidoides, was also able to decrease intracellular glutathione
levels, an important metabolite involved in the clearance of
xenobiotics and the detoxification of reactive species (Xie, 2009).
The variations of intracellular glutathione may be related to
different effects, i.e., (a) inhibition/induction of enzymes involved
in its biosynthesis, such as glutamate-cysteine ligase (GCL)
and glutathione synthase (Lu, 2013); (b) the increase (or the
inhibition) of GSH eﬄux from cells (Aw et al., 1986; Fernandez-
Checa et al., 1988; Lu et al., 1990) which may be associated also
with cell death (De Nicola and Ghibelli, 2014); (c) the formation
(and the possible release) of GSH-adducts could also cause a
reduction of the detectable intracellular glutathione (if it is not
compensated by a new GSH synthesis) (Blair, 2010); finally (d) a
modulation of glutathione transferase (GST) activity could also
explain changes in both intra- and extracellular glutathione levels
(Tolson and Wang, 2010). As for (a), the presence of active
compounds in Solanum paniculatum, Cordia verbenacea and
Lippia sidoides could be depleting glutathione in a similar manner
BSO does, i.e., by inhibiting the GCL enzyme (Marengo et al.,
2008). In order to identify these active compounds, a bioguided
isolation strategy would be needed. Literature data reports that
polyphenols such as gallic acid and derivatives, flavonoids such
as luteolin, chrysin and apigenin, among others, induce GCL
expression rather than inhibiting its activity (Panich et al., 2012;
Huang et al., 2013). (b) is less likely to happen due to cell
death as we are working with concentrations of plant extracts
that are more than ten times lower than their maximum non-
toxic concentration (>1000 µg/mL). More refined experiments
would be needed to attest the formation of GSH-adducts, as
stated in (c). As per (d) is another target that should be
studied if the mechanism of glutathione depletion needs to be
unveiled.
Depletion could be also linked to a non-functional γ-glutamyl
cycle. This cycle serves as a continuous source of cysteine,
which plays a key role in glutathione synthesis. GGT is an
enzyme that first catalyzes the cleavage of glutathione on its
γ-glutamyl-cysteine bond. Cysteinylglycine is then broken down
by a dipeptidase to form glycine and cysteine. Cells reuptake
those amino acids in order to synthesize more glutathione.
Deficiency of GGT activity could potentially lower glutathione
levels due to loss of cysteine (as glutathione) in the urine.
Therefore, glutathione synthesis would be impaired due to the
absence of this amino acid (Chevez-Barrios et al., 2000; Lu, 2013).
Indeed, the reduction of glutathione levels found in HepG2
cells treated with Cordia verbenacea turned out to be due –at least
in part- by its ability to decrease GGT activity. However, Solanum
paniculatum and Lippia sidoides did not affect GGT activity in a
significant way, so glutathione levels in those cases could have
been affected via other mechanisms.
Dereplication of the active principles responsible for this
activity can be attempted from our HPTLC analysis. The
flavonoid luteolin was found in Lippia sidoides and gallic acid
was found in Solanum paniculatum. Those compounds have
been reported to deplete intracellular glutathione levels. A study
published by Balyan et al. (2015) demonstrated that intracellular
glutathione levels were significantly depleted by luteolin in the
human melanoma SK-MEL-28 cell line. This was explained
by an inhibition of glutathione S-transferase (GST) activity
via competitive reversible and irreversible mixed mechanisms
(Balyan et al., 2015). Another study published by Locatelli et al.
(2009) showed that gallic acid was able to deplete intracellular
glutathione levels in melanoma cells through inhibition of the
activity of γ-Glutamyl-cysteine synthetase. Gallic acid has been
also proven to inhibit GGT activity in mice (Mahajan and
Mahmood, 2009).
Last but not least, P-gp activity was not affected by any of the
extracts. This is a positive finding taking into consideration that
this is one of the most important targets in preclinical studies.
As for E. mulungu, it did not affect any of the targets selected
in this work, however, it increased glutathione levels. Although
this effect is not harmful in itself, its ability to cause HDIs cannot
be ruled out by helping to metabolize other drugs through the
formation of GSH adducts. We should still warn that other
types of interactions may be important in this case. In Brazil,
this medicinal plant has been used for a long time as a natural
sedative. Indeed there is in vivo data validating its diazepam-like
activity, so caution is warranted when patients have to combine
this with other central nervous system (CNS) active prescription
medicines, drive or operate potentially dangerous machines at
work (Onusic et al., 2002).
Brazilian regulations on herbal medicines have been changing
over the years. Improving the regulatory framework for herbal
medicines is necessary due to the increased number of unlicensed
products on the market. ANVISA has a guide for such studies,
called “Guide for the conduction of non-clinical toxicology
studies and safety pharmacology required for the development of
medicines” (Carvalho et al., 2014).
Information about HDI for the plants to be used by
the Brazilian Health system is generally scarce. Those used
worldwide, such as Allium sativum and Cynara scolymus have
some interaction data already documented (Mazzari and Prieto,
2014a). Such information is even more scarce for the Brazilian
native species, with Paullinia cupana as an exception (Rodrigues
et al., 2012).
Evidence about HDI is, in most cases, based on alleged
relations of the plant constituents with known mechanisms
of action. For example, there are no published studies about
potential HDI of Maytenus ilicifolia. However, it is known that
quercetin and kaempferol are P-gp modulators found in the
plant extract. Therefore, it is assumed but not attested, that HDI
are likely to happen in this case (Zhou et al., 2004). As an
example, we detected quercetin in our Lippia sidoides sample but
such amount was not enough to cause changes in P-gp activity
in vitro.
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Patients in Brazil do not make exclusive use of registered
herbal medicines manufactured by the industry. Local
pharmacies are legally allowed to produce pharmaceutical
products, which could contain a medicinal plant in the
formulation. In this case, the final product does not require the
approval of ANVISA to be sold to the patient. Furthermore,
medicinal plants are also used in homemade preparations and in
those cases data on interactions are even scarcer. ANVISA says
that it is time to focus the research on Brazilian native plants in
order to reveal the real interactions they could cause. This could
improve the knowledge of users, health professionals and even
public decision makers.
Experimental studies, such as preclinical studies, which are the
subject of this report, are therefore highly important to elucidate
underlying mechanisms. Those preclinical studies will serve as
guidance for future clinical studies. Eventually, more potential
cases of HDI could be prevented rather than being late diagnosed
by the pharmacovigilance systems (De Smet, 2007).
CONCLUSION
This preclinical study evidences the possibility that the
administration of some of these herbal medicines may be able
to cause in vitro disturbances to metabolic mechanisms. More
refined studies would be necessary to ascertain the in vivo
and/or clinical significance of such interactions. At this point,
we can suggest that active pharmacovigilance is recommended
for Cordia verbenaceae, Lippia sidoides, and especially in the
case of Solanum paniculatum for which an in vitro hPXR-
mediated reduction of CYP3A4 gene expression accompanied by
significant depletion of glutathione is suggested here for the first
time.
Although further studies are needed in order to attest the
clinical relevance of our findings, we hope that this work will
contribute to stimulate similar research toward the regulation of
the quality and safety of these herbal medicines in Brazil.
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